Richmond Pharmacology presents Improving Clinical Trial Design at the BAPU 4th 2-yearly Symposium 2012

Posted:
1
October 2012

Richmond Pharmacology presents �Improving Clinical Trial Design�at the BAPU 4th 2-yearly Symposium 2012

The Belgian Association of Phase 1 Units (BAPU) will host its 4th 2-yearly symposium this year in Antwerp, taking place 9th November 2012. The focus of this year�s meeting is modernising and innovation in early clinical drug development towards 2020.Founded in January 2005, BAPU represents the Belgian phase I clinical research units from both the pharmaceutical industry and academia. One of its primary objectives is to facilitate collaboration between Belgian phase I units as well as international phase I units and regulatory authorities.Invited on behalf of BAPU, Dr Ulrike Lorch�s presentation on Improving Clinical Trial Design will describe the benefit of adaptive design in First into Human and Early Phase Combination Studies, showing how its use, compared to conventional study designs, can lead to comprehensive time savings in early research programs.Click here to view full program and to registerWatch our latest presentation on Adaptive Study Design

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more